Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy

References

• Titanji K, De Milito A, Cagigi A, Thorstensson R, Grützmeier S, Atlas A, Hejdeman B, Kroon FP, Lopalco L, Nilsson A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006; 108:1580-7; PMID:16645169; http://dx.doi.org/10.1182/blood-2005-11-013383
   PubMed Web of Science ®Google Scholar
• De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, Narita M, Grutzmeier S, Sönnerborg A, Chiodi F. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004; 103:2180-6; PMID:14604962; http://dx.doi.org/10.1182/blood-2003-07-2375
   PubMed Web of Science ®Google Scholar
• Terpstra FG, Al BJ, Roos MT, De Wolf F, Goudsmit J, Schellekens PT, Miedema F. Longitudinal study of leukocyte functions in homosexual men seroconverted for HIV: rapid and persistent loss of B cell function after HIV infection. Eur J Immunol 1989; 19:667-73; PMID:2567244; http://dx.doi.org/10.1002/eji.1830190415
   PubMed Web of Science ®Google Scholar
• Hart M, Steel A, Clark SA, Moyle G, Nelson M, Henderson DC, Wilson R, Gotch F, Gazzard B, Kelleher P. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol 2007; 178:8212-20; PMID:17548660; http://dx.doi.org/10.4049/jimmunol.178.12.8212
   PubMed Web of Science ®Google Scholar
• Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-45; PMID:19319142; http://dx.doi.org/10.1038/nri2524
   PubMed Web of Science ®Google Scholar
• Cubas RA, Mudd JC, Savoye AL, Perreau M, van Grevenynghe J, Metcalf T, Connick E, Meditz A, Freeman GJ, Abesada-Terk G Jr, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 2013; 19:494-9; PMID:23475201; http://dx.doi.org/10.1038/nm.3109
   PubMed Web of Science ®Google Scholar
• Massanella M, Negredo E, Clotet B, Blanco J. Immunodiscordant responses to HAART–mechanisms and consequences. Expert Rev Clin Immunol 2013; 9:1135-49; PMID:24168417; http://dx.doi.org/10.1586/1744666X.2013.842897
   PubMed Web of Science ®Google Scholar
• Pedersen RH, Lohse N, Ostergaard L, Sogaard OS. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011;12:323-33; PMID:21059168; http://dx.doi.org/10.1111/j.1468-1293.2010.00892.x
   PubMed Web of Science ®Google Scholar
• Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992; 117:314-24; PMID:1637028; http://dx.doi.org/10.7326/0003-4819-117-4-314
   PubMed Web of Science ®Google Scholar
• Filice GA, Darby CP, Fraser DW. Pneumococcal bacteremia in Charleston County, South Carolina. Am J Epidemiol 1980; 112:828-35; PMID:7457474
   PubMed Web of Science ®Google Scholar
• Mufson MA, Oley G, Hughey D. Pneumococcal disease in a medium-sized community in the United States. JAMA 1982; 248:1486-9; PMID:7109171; http://dx.doi.org/10.1001/jama.1982.03330120044028
   PubMed Web of Science ®Google Scholar
• Redd SC, Rutherford GW, 3rd, Sande MA, Lifson AR, Hadley WK, Facklam RR, Spika JS. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990; 162:1012-7; PMID:2230229; http://dx.doi.org/10.1093/infdis/162.5.1012
   PubMed Web of Science ®Google Scholar
• Selwyn PA, Feingold AR, Hartel D, Schoenbaum EE, Alderman MH, Klein RS, Friedland GH. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988; 2:267-72; PMID:3140832; http://dx.doi.org/10.1097/00002030-198808000-00005
   PubMed Web of Science ®Google Scholar
• Domingo P, Puig M, Pericas R, Mirelis B, Prats G. Invasive pneumococcal disease in HIV-1 infected patients. Lancet 1996; 347:1414; PMID:8637373; http://dx.doi.org/10.1016/S0140-6736(96)91059-4
   PubMed Web of Science ®Google Scholar
• Boschini A, Smacchia C, Di Fine M, Schiesari A, Ballarini P, Arlotti M, Gabrielli C, Castellani G, Genova M, Pantani P, et al. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis 1996; 23:107-13; PMID:8816138; http://dx.doi.org/10.1093/clinids/23.1.107.
   PubMed Web of Science ®Google Scholar
• Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:857-62; PMID:8603963; http://dx.doi.org/10.1093/infdis/173.4.857
   PubMed Web of Science ®Google Scholar
• Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE, Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32:794-800; PMID:11229848; http://dx.doi.org/10.1086/319218
   PubMed Web of Science ®Google Scholar
• Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Khoshnood K, Holford TR, Schuchat A. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191:2038-45; PMID:15897989; http://dx.doi.org/10.1086/430356
   PubMed Web of Science ®Google Scholar
• Saindou M, Chidiac C, Miailhes P, Voirin N, Baratin D, Amiri M, Livrozet JM, Touraine JL, Trepo C, Peyramond D, et al. Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods. HIV Med 2008; 9:203-7; PMID:18298578; http://dx.doi.org/10.1111/j.1468-1293.2008.00546.x
   PubMed Web of Science ®Google Scholar
• Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, Liñares J, Gudiol F; Spanish Pneumococcal Infection Study Network (G03/103). Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Internal Med 2005; 165:1533-40; PMID:16009870; http://dx.doi.org/10.1001/archinte.165.13.1533
   PubMed Web of Science ®Google Scholar
• Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, Pedersen C, Pedersen G, Sørensen HT, Obel N. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47:1345-53; PMID:18834317; http://dx.doi.org/10.1086/592692
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132:182-90; PMID:10651598; http://dx.doi.org/10.7326/0003-4819-132-3-200002010-00003
   PubMed Web of Science ®Google Scholar
• Jordano Q, Falco V, Almirante B, Planes AM, del Valle O, Ribera E, Len O, Pigrau C, Pahissa A. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623-8; PMID:15156452; http://dx.doi.org/10.1086/420933
   PubMed Web of Science ®Google Scholar
• Grau I, Ardanuy C, Linares J, Podzamczer D, Schulze MH, Pallares R. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med 2009; 10:488-95; PMID:19459987; http://dx.doi.org/10.1111/j.1468-1293.2009.00717.x
   PubMed Web of Science ®Google Scholar
• Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, Smith RD, Slack M, Delpech VC. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS 2012; 26:87-94; PMID:22008657; http://dx.doi.org/10.1097/QAD.0b013e32834dcf27
   PubMed Web of Science ®Google Scholar
• USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis 1995; 21(Suppl 1):S32-43; PMID:8547510
   PubMedGoogle Scholar
• 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. MMWR Recomm Rep 1997; 46:1-46; PMID:9214702
   PubMedGoogle Scholar
• 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30(Suppl 1):S29-65; PMID:10770913; http://dx.doi.org/10.1086/313848
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Masur H, Holmes KK, USPHS, Infectious Disease Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons–2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1-52; PMID:12081007
   PubMedGoogle Scholar
• Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207; PMID:19357635
   PubMedGoogle Scholar
• French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11; PMID:10902624; http://dx.doi.org/10.1016/S0140-6736(00)02377-1
   PubMed Web of Science ®Google Scholar
• Loeliger AE, Rijkers GT, Aerts P, Been-Tiktak A, Hoepelman AI, van Dijk H, Borleffs JC. Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients. FEMS Immunol Med Microbiol 1995; 12:33-41; PMID:8580899; http://dx.doi.org/10.1111/j.1574-695X.1995.tb00171.x
   PubMed Web of Science ®Google Scholar
• Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996; 173:83-90; PMID:8537687; http://dx.doi.org/10.1093/infdis/173.1.83
   PubMed Web of Science ®Google Scholar
• Janoff EN, Fasching C, Ojoo JC, O'Brien J, Gilks CF. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. J Infect Dis 1997; 175:975-8; PMID:9086163; http://dx.doi.org/10.1086/514004
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000; 19:886-94; PMID:11115712; http://dx.doi.org/10.1016/S0264-410X(00)00232-2
   PubMed Web of Science ®Google Scholar
• Lesprit P, Pedrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, Katlama C, Yéni P, Morineau P, Delfraissy JF, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21:2425-34; PMID:18025879; http://dx.doi.org/10.1097/QAD.0b013e3282887e91
   PubMed Web of Science ®Google Scholar
• Falco V, Jordano Q, Cruz MJ, Len O, Ribera E, Campins M, Crespo M, Ocaña I, Rodrigo MJ, Pahissa A. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine 2006; 24:2567-74; PMID:16423429; http://dx.doi.org/10.1016/j.vaccine.2005.12.021
   PubMed Web of Science ®Google Scholar
• Hung CC, Chang SY, Su CT, Chen YY, Chang SF, Yang CY, Liu WC, Wu CH, Chang SC. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med 2010; 11:54-63; PMID:19659943; http://dx.doi.org/10.1111/j.1468-1293.2009.00744.x
   PubMed Web of Science ®Google Scholar
• Sogaard OS, Schonheyder HC, Bukh AR, Harboe ZB, Rasmussen TA, Ostergaard L, Lohse N. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS 2010; 24:1315-22; PMID:20559037; http://dx.doi.org/10.1097/QAD.0b013e328339fe0b
   PubMed Web of Science ®Google Scholar
• Slayter KL, Singer J, Lee TC, Kayhty H, Schlech WF. Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147). Int J STD AIDS 2013; 24:227-31; PMID:23535358; http://dx.doi.org/10.1177/0956462412472450
   PubMed Web of Science ®Google Scholar
• Lu CL, Chang SY, Chuang YC, Liu WC, Su CT, Su YC, Chang SF, Hung CC. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy. Vaccine 2014; 32:1031-5; PMID:24440112; http://dx.doi.org/10.1016/j.vaccine.2014.01.009
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999; 18:524-30; PMID:10519943; http://dx.doi.org/10.1016/S0264-410X(99)00240-6
   PubMed Web of Science ®Google Scholar
• Kerneis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boelle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis 2014; 58(8):1130-9; PMID:24415637; http://dx.doi.org/10.1093/cid/cit937
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-8; PMID:14523142; http://dx.doi.org/10.1056/NEJMoa035060
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra EE, Molyneux ME, Gilks CF. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22; PMID:20200385; http://dx.doi.org/10.1056/NEJMoa0903029
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816-9; PMID:23051612.
   PubMedGoogle Scholar
• Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. ( Accessed Mar 30, 2014, at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.).
   Google Scholar
• EACS guidelines for the treatment of HIV. Version 7.0. Oct 2013. 2013. at http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf).
   Google Scholar
• WHO Publication. Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 2012; 30:4717-8; PMID:22621828; http://dx.doi.org/10.1016/j.vaccine.2012.04.093
   PubMed Web of Science ®Google Scholar
• Public Health England. Immunisation against infectious disease. Pneumococcal: the green book, chapter 25. Updated on 4 December 2013.
   Google Scholar
• Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother 2012; 8:161-73; PMID:22426374; http://dx.doi.org/10.4161/hv.18432
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Averbuch D, Maury S, Engelhard D. Pneumococcal immunization in immunocompromised hosts: where do we stand? Expert Rev Vaccines 2014; 13:59-74; PMID:24308578; http://dx.doi.org/10.1586/14760584.2014.859990
   PubMed Web of Science ®Google Scholar
• Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, Holder PF, O'Brien WA, Whitney CG, Butler JC, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20:545-53; PMID:11672921; http://dx.doi.org/10.1016/S0264-410X(01)00347-4
   PubMed Web of Science ®Google Scholar
• Miiro G, Kayhty H, Watera C, Tolmie H, Whitworth JA, Gilks CF, French N. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005; 192:1801-5; PMID:16235180; http://dx.doi.org/10.1086/497144
   PubMed Web of Science ®Google Scholar
• Chen M, Ssali F, Mulungi M, Awio P, Yoshimine H, Kuroki R, Furumoto A, Tanimura S, Kityo C, Nagatake T et al. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. Vaccine 2008; 26:4962-8; PMID:18639599; http://dx.doi.org/10.1016/j.vaccine.2008.06.093
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum ML, Weintrob A, Agan BK, Medina S, Rahkola J, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010; 202:1114-25; PMID:20795819; http://dx.doi.org/10.1086/656147
   PubMed Web of Science ®Google Scholar
• Penaranda M, Payeras A, Cambra A, Mila J, Riera M. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 2010; 24:1226-8; PMID:20299956; http://dx.doi.org/10.1097/QAD.0b013e3283389de5
   PubMed Web of Science ®Google Scholar
• Sogaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, Schønheyder HC, Østergaard L. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010; 51:42-50; PMID:20504165; http://dx.doi.org/10.1086/653112
   PubMed Web of Science ®Google Scholar
• Lu CL, Hung CC, Chuang YC, Liu WC, Su CT, Hsiao CF, Tseng YT, Su YC, Chang SF, Chang SY. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients. Vaccine 2012; 30:3526-33; PMID:22484349; http://dx.doi.org/10.1016/j.vaccine.2012.03.070
   PubMed Web of Science ®Google Scholar
• Ho YL, Brandao AP, de Cunto Brandileone MC, Lopes MH. Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil. Vaccine 2013; 31:4047-53; PMID:23684823; http://dx.doi.org/10.1016/j.vaccine.2013.04.065
   PubMed Web of Science ®Google Scholar
• Lu CL, Hung CC, Chuang YC, Liu WC, Su CT, Su YC, Chang SF, Chang SY, Chang SC. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother 2013; 9:398-404; PMID:23291936; http://dx.doi.org/10.4161/hv.22836
   PubMed Web of Science ®Google Scholar
• Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34:813-21; PMID:11850863; http://dx.doi.org/10.1086/339044
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Feb 12, 2013. (Accessed Mar 30, 2014, at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf).
   Google Scholar
• Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009; 49:205-12; PMID:19508165; http://dx.doi.org/10.1086/599827
   PubMed Web of Science ®Google Scholar
• Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51; PMID:16249418; http://dx.doi.org/10.1001/jama.294.16.2043
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46; PMID:12724479; http://dx.doi.org/10.1056/NEJMoa022823
   PubMed Web of Science ®Google Scholar
• Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, Schaffner W, Lynfield R, Thomas AR, Li J, et al. Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Internal Med 2006; 144:1-9; PMID:16389249; http://dx.doi.org/10.7326/0003-4819-144-1-200601030-00004
   PubMed Web of Science ®Google Scholar
• Cohen AL, Harrison LH, Farley MM, Reingold AL, Hadler J, Schaffner W, Lynfield R, Thomas AR, Campsmith M, Li J, et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010; 24:2253-62; PMID:20671543; http://dx.doi.org/10.1097/QAD.0b013e32833d46fd
   PubMed Web of Science ®Google Scholar
• Burgos J, Penaranda M, Payeras A, Villoslada A, Curran A, Garau M, Riera M, Crespo M, Navarro J, Van den Eynde E. Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in children. J Acquir Immune Defic Syndr 2012; 59:31-8; PMID:22156821; http://dx.doi.org/10.1097/QAI.0b013e31823d0f5f
   PubMed Web of Science ®Google Scholar
• Kourtis AP, Ellington S, Bansil P, Jamieson DJ, Posner SF. Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine. J Acquir Immune Defic Syndr 2010; 55:128-31; PMID:20622675; http://dx.doi.org/10.1097/QAI.0b013e3181e8ed15
   PubMed Web of Science ®Google Scholar
• Antiretroviral Therapy Cohort C. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-9; PMID:18657708; http://dx.doi.org/10.1016/S0140-6736(08)61113-7
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM, Egger M; Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005;366:378-84; PMID:16054937; http://dx.doi.org/10.1016/S0140-6736(05)67022-5
   PubMed Web of Science ®Google Scholar